Bevacizumab alone or in combination with chemotherapy in glioblastomas?--authors' reply

Affiliations

¹ Department of Neuro-Oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands. Electronic address: m.vandenbent@erasmusmc.nl.
² Department of Neuro-Oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands.

Comment

Martin J van den Bent et al. Lancet Oncol. 2014 Oct.

. 2014 Oct;15(11):e473-4.

doi: 10.1016/S1470-2045(14)70453-X.

¹ Department of Neuro-Oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands. Electronic address: m.vandenbent@erasmusmc.nl.
² Department of Neuro-Oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands.

No abstract available

Comment on

Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.
Taal W, Oosterkamp HM, Walenkamp AM, Dubbink HJ, Beerepoot LV, Hanse MC, Buter J, Honkoop AH, Boerman D, de Vos FY, Dinjens WN, Enting RH, Taphoorn MJ, van den Berkmortel FW, Jansen RL, Brandsma D, Bromberg JE, van Heuvel I, Vernhout RM, van der Holt B, van den Bent MJ. Taal W, et al. Lancet Oncol. 2014 Aug;15(9):943-53. doi: 10.1016/S1470-2045(14)70314-6. Epub 2014 Jul 15. Lancet Oncol. 2014. PMID: 25035291 Clinical Trial.
Bevacizumab alone or in combination with chemotherapy in glioblastomas?
Raza S, Firwana B, Doll DC. Raza S, et al. Lancet Oncol. 2014 Oct;15(11):e472-3. doi: 10.1016/S1470-2045(14)70396-1. Lancet Oncol. 2014. PMID: 25281464 No abstract available.